[
  {
    "ts": null,
    "headline": "THW: Income Investors Likely To Face A Massive Distribution Cut",
    "summary": "THW: Income Investors Likely To Face A Massive Distribution Cut",
    "url": "https://finnhub.io/api/news?id=a3da899ef4a9d4e7d94a10749f922b80b4e7533ebde280775acd20c87ded1bb4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748164929,
      "headline": "THW: Income Investors Likely To Face A Massive Distribution Cut",
      "id": 134693394,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3da899ef4a9d4e7d94a10749f922b80b4e7533ebde280775acd20c87ded1bb4"
    }
  },
  {
    "ts": null,
    "headline": "Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success",
    "summary": "Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands out and TIL stock is a buy.",
    "url": "https://finnhub.io/api/news?id=ab190386440498a4befe1055732d00019dd5c617225d069c70eb160a6e718ce2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748156976,
      "headline": "Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success",
      "id": 134692858,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2205530499/image_2205530499.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Instil Bio eyes key NSCLC catalyst with Phase 2 China data in 2H 2025 and a distinct U.S. strategy. Learn why AXN-2510 stands out and TIL stock is a buy.",
      "url": "https://finnhub.io/api/news?id=ab190386440498a4befe1055732d00019dd5c617225d069c70eb160a6e718ce2"
    }
  }
]